cytotoxic t lymphocytes in treating patients with malignancies with bk and/or jc virus

Conditions: Acquired Immunodeficiency Syndrome; BK Virus Infection; Human Immunodeficiency Virus; JC Virus Infection; Malignant Neoplasm; Merkel Cell Carcinoma; Merkel Cell Polyomavirus Infection; Viral Encephalitis

Summary: this phase ii trial studies how well donor cytotoxic t lymphocytes work in treating patients with malignancies with bk and/or jc virus. cytotoxic t lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with bk and/or jc virus.

primary objective: i. to assess the efficacy, feasibility and safety of administering most closely human leukocyte antigen (hla)-matched bk specific cytotoxic t lymphocyte (ctl) lines (bk-ctls) generated by ex vivo expansion to mediate antiviral activity in patients with any type of malignancies, and/or human immunodeficiency virus (hiv)/acquired immunodeficiency syndrome (aids), and/or history of solid organ transplant with bk and jc infections. secondary objective: i. to assess the persistence of the administered bk-ctls generated by ex vivo expansion in patients with any type of malignancies, and/or hiv/aids, and/or history of solid organ transplant with bk and jc infections. outline: patients receive allogeneic bk-specific cytotoxic t-lymphocytes intravenously (iv) over 30 minutes. patients achieving partial response, stable disease, or progressive disease are eligible for 7 additional infusions of ctl occurring at least 2 weeks after the previous ctl infusion if they meet the eligibility criteria for subsequent therapy. after completion of study treatment, patients are followed up periodically for 12 months.

Eligibility criteria:
inclusion criteria: * patients with any type of malignancies; and/or hiv/aids; and/or history of solid organ transplant; and/or merkel polyoma-virus related merkel cell tumor(s) with measurable disease on imaging per response evaluation criteria in solid tumors (recist) criteria * patients with microscopic hematuria or biopsy proven bk nephritis and urine or blood polymerase chain reaction (pcr) positive for bk virus and/or jc viral encephalitis * clinical status at enrollment to allow tapering of steroids to less than 0.5 mg/kg/day of prednisone * patients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for ctl infusion * once patients have completed 6-week safety and efficacy assessments after completion of the last anti-bk ctl infusion, patients will be eligible for enrollment on other supportive care protocols * written informed consent from patient and/or signed assent from patient, parent or guardian * negative pregnancy test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization; women of child bearing potential must be willing to use an effective contraceptive measure while on study exclusion criteria: * patients receiving prednisone \> 0.5 mg/kg/day at time of enrollment, or have received anti-thymocyte globulin (atg) within 14 days or have received donor lymphocyte infusion (dli) or campath within 28 days of enrollment * patients with other uncontrolled infections (except hiv/aids); for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment; for fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment; progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection; persisting fever without other signs or symptoms will not be interpreted as progressing infection * patients with active acute graft-versus-host disease (gvhd) grades ii-iv